Neonatal abstinence syndrome due to prenatally citalopram exposure: A case report

Sara Erol, M.D., Beyza Ozcan, M.D., Iştemi H. Celik, M.D., Assoc. Prof., Ahmet Y. Bas, M.D., Assoc. Prof. and Nihal Demirel, M.D., Assoc. Prof.

ABSTRACT
Neonatal abstinence syndrome (NAS) due to prenatally exposure to citalopram can develop during the first days of life even with low dose of drug exposure. Supportive management is the first choice but phenobarbital can be used in treatment of this syndrome. Breastfeeding should not be interrupted. These neonates should be followed both for NAS and neurodevelopmental outcome. In this article, we reported a newborn with NAS due to citalopram exposure with a lower dose than previously reported in the literature, during the last six months of pregnancy. Phenobarbital was used because of non-pharmacological treatment failure.

Key words: neonatal abstinence syndrome, citalopram, Phenobarbital.

INTRODUCTION
Psychiatric disorders such as major depression, anxiety, and obsessive compulsive disorders are common during and after pregnancy. A large study from United States showed a prevalence of 13% for mood and anxiety disorders in pregnant or postpartum women. Antidepressants are commonly used to treat these disorders. Adequate treatment of depression during pregnancy is of great importance for maternal, fetal and neonatal health. Selective serotonin reuptake inhibitors (SSRIs) are the most prescribed group of antidepressants, also in pregnant women. SSRIs, especially paroxetine, fluoxetine and sertraline, during late pregnancy may lead to neonatal abstinence syndrome (NAS). This syndrome is also called as poor neonatal adaptation. It includes symptoms such as jitteriness, convulsion, abnormal crying, feeding problems, respiratory distress and hypoglycemia. We reported a newborn with NAS due to citalopram exposure during the last six months of pregnancy.

Case report
A 3010 g male infant, length 50 cm and head circumference 33 cm, was delivered by cesarean section at 36 weeks of gestation. The mother was 40 year old and had good prenatal care and history of major depression. She had been taking citalopram 10mg/day beyond the last two trimesters of her pregnancy. At birth, the infant had Apgar scores of 8, 9 and 10 at 1, 5 and 10 minutes. The patient was admitted to the neonatal intensive care unit because of respiratory distress in the first hour after birth. On admission, he was tachypneic with a respiratory rate of 68 per minute with intercostal and subcostal retractions. Complete blood count, arterial blood gases, blood glucose level and serum electrolytes including calcium and magnesium, and chest X-ray were in normal ranges. Serum C-reactive protein (CRP) was negative. Respiratory distress was treated with supplemental oxygen and gradually improved during the first day.

On postnatal day 3, jitteriness and hyperirritability occurred. Hypoglycemia (25 mg/dl) and hypocalcaemia (ionized calcium: 3.1 mg/dl) were diagnosed. Jitteriness and hyperirritability continued despite intravenous glucose and calcium replacement treatment. Muscle tone increased within hours and opisthotonic posture began to appear intermittently. He had hyperreactive deep tendon and exaggerated Moro reflexes. The modified Finnegan score was performed for NAS. The result was found as 8, corresponding to severe NAS. Infant was subsequently scored at least every 2 hours by the neonatologist. Non-
pharmacological treatments such as minimizing environmental stimuli, adequate rest and sleep, breastfeeding and swaddling were started. Phenobarbital as 5 mg/kg/day divided every 12 hours was started because 3 consecutive scores were > 8 despite non-pharmacological treatments. Cranial USG and EEG were performed for differential diagnosis with normal results. After three days of phenobarbital treatment, jitteriness, muscle rigidity and hyperirritability reduced; the modified Finnegan score was < 8 and phenobarbital dose was gradually decreased and stopped on postnatal day 14. The clinical signs gradually improved at postnatal day 10. The patient was discharged with normal physical examination on day 16.

DISCUSSION

Placental transfer of SSRIs has been demonstrated experimentally both in animals and in humans. These drugs had not placental metabolism. Placental drug transfer is also determined by duration of drug exposure, liposolubility, protein binding, volume of distribution and other pharmacokinetic factors. By definition, antidepressant abstinence or discontinuation syndrome occurs in the first few days after abrupt drug cessation, as after delivery, when the drug concentrations from the newborn’s serum are not detectable or too low to have any biological effect; most common reported symptoms include irritability, sleep disturbances, abnormal crying, rigidity and tremor. Diagnosis is usually performed by prenatal history, clinical findings and Finnegan score. Finnegan score was originally developed to diagnose neonatal opioid abstinence but has also been used to assess neonatal symptoms in SSRI exposed infants.

The recent study showed that most of infants born to mothers with SSRI treatment during pregnancy were healthy in the neonatal period. Severe abstinence syndrome was reported in 3-13% in these studies whereas mild abstinence rate was 22% due to maternal SSRIs exposure. The symptoms mainly arise from the central nervous system. Hypoglycemia and respiratory symptoms were found commonly. Neonatal abstinence syndrome due to SSRI had been reported in 93 cases including 6 cases with citalopram by 2003. A more recent retrospective cohort study by Forsberg et al. evaluated 71 newborns exposed to citalopram during the third trimester with a median dosage 20 mg/day (5-80 mg/day). Severe (Finnegan score ≥8) and mild (Finnegan score 4-7) abstinence treated with non-pharmacological therapy were diagnosed in 2 and 18 newborns, respectively. Respiratory distress and hypoglycemia were found in 5 and 8 newborns whereas 10 of the newborns were premature. They did not find any correlation between SSRI and respiratory distress. Nordeng et al. reported 5 infants with NAS due to SSRIs including 1 with citalopram. He was a male infant exposed to citalopram with the dosage of 20 mg/day starting from 5th month of pregnancy and increased to 30 mg/day 2 months before delivery. He did not need medical treatment (Finnegan scores 4-6) and was discharged at the postnatal 7th day. There is no safe citalopram dose to prevent NAS. A lower dose exposure than previous studies such as our patient, 10 mg/kg, may lead to NAS. In our patient, respiratory distress which was usually accompanied with SSRI use in pregnancy resolved in 24 h. Hypoglycemia and hypocalcaemia responded intravenous glucose and calcium as reported in previous studies. Since our patient was a premature, the reason for hypoglycemia and hypocalcaemia could be prematurity not NAS. But, neuromuscular findings were resolved after phenobarbital treatment.

Serum levels of citalopram in infants were reported to be 0.9%-4.3% of the mothers’ serum levels 2 weeks to 2 months after delivery. Infant citalopram intake dose by breastfeeding was reported to be 0.7%-9% of maternal dose after adjusting weight and considering citalopram bioavailability as 100%. Breastfeeding should be offered in these patients because these studies did not reveal citalopram-associated effects in infants during breastfeeding whereas formula feeding of these infants was found to be a risk factor for NAS. Therapeutic drug monitoring by measuring citalopram concentrations in serum of both mother and newborn may prevent drug-associated side effects. With today’s extremely short duration of hospital stay for newborns and the longer half-life of SSRIs, the symptoms may even occur after discharge from hospital. In our center, the infants exposed to antidepressants stayed in hospital at least 72-96 hours.

Studies on long term effects of prenatal SSRIs are limited. Maternal depression is a major risk factor for neurodevelopmental problems. There seem to be no major effects, but further studies are needed.

Management of the neonate includes both pharmacological and non-pharmacological care. Non-pharmacological therapy is the first option
in all cases, and may be sufficient in cases of mild abstinence. Non-pharmacological therapy is easily acceptable, less expensive, and less controversial. Non-pharmacological therapy can be attempted in all infants before initiating pharmacological therapy. Successful management comprises gentle handling, demand feeding, and careful avoidance of waking the sleeping infant. Continuous minimal stimulation practices with dim light and low noise must be implemented in all neonates. Frequent feeds, high calorie formula, and thickened feeds may meet nutritional and metabolic demands. Phenobarbital is a drug of choice for non-opiate NAS. Phenobarbital does not prevent seizures at the dosage administered for abstinence, nor improves gastrointestinal symptoms. We observed that neurological symptoms were improved in our patient.

In conclusion, neonatal maladaptation and NAS due to prenatally SSRIs’ exposure such as citalopram can develop in first days of life even with low dose of drug exposure. Supportive management is the first choice but phenobarbital can be used in treatment of this syndrome. Breastfeeding should be continued preferably. These neonates should be followed both for NAS and neurodevelopmental outcome.

REFERENCES